Botulinum Toxin Relieves Anxiety and Depression in Patients with Hemifacial Spasm and Blepharospasm.

Hongjuan Dong,Shanghua Fan,Ying Luo,Bin Peng
DOI: https://doi.org/10.2147/ndt.s181820
IF: 2.989
2018-01-01
Neuropsychiatric Disease and Treatment
Abstract:Objective: To explore the efficacy of botulinum toxin type A (BTX-A) therapy in relieving anxiety and depression in patients with hemifacial spasm (HFS) and benign essential blepharospasm (BEB). Patients and method: Ninety idiopathic HFS patients and 90 BEB patients were enrolled. The anxiety and depression status were evaluated by self-rating anxiety scale (SAS) and self-rating depression scale (SDS), respectively, before and after the injection of BTX-A. Results: Before treatment, the SAS and SDS scores of HFS patients were 41.25 +/- 6.35 and 42.25 +/- 7.57, respectively. The SAS scores were 40.17 +/- 8.36 for males and 43.56 +/- 6.10 for females (P=0.031). The SDS scores were 40.25 +/- 6.46 for males and 45.48 +/- 7.31 for females (P=0.008). After treatment, the SAS and SDS scores were 30.12 +/- 4.35 and 30.58 +/- 4.89, respectively. There was a significant difference in the SAS and SDS scores before and after treatment. Before treatment, the SAS scores of male and female BEB patients were 56.45 +/- 8.75 and 60.89 +/- 9.11, respectively, and the SDS scores of male and female BEB patients were 57.90 +/- 7.93 and 60.12 +/- 8.35, respectively. After treatment, the SAS score was 38.17 +/- 3.67 and the SDS score was 38.12 +/- 4.15, with a significant difference in before and after treatment scores. Conclusion: In HFS and BEB, especially in female patients, there is an association with anxiety and depression. BTX-A can improve the symptoms of anxiety and depression.
What problem does this paper attempt to address?